Takeda Kazakhstan is part of the global biopharmaceutical group of Takeda Pharmaceuticals in Kazakhstan. Furthermore, Kazakhstan is considered a key country for Takeda's investments within the "Growth & Emerging Markets" (GEM) business unit.

Takeda Kazakhstan ranks sixth among the top 10 pharmaceutical companies and holds a 3% share of the pharmaceutical market in Kazakhstan.

Our employees are the foundation of our success. We create a diverse, inclusive, safe, and open work environment where everyone has the opportunity to reach their full potential, leading to professional and personal growth.

Thanks to our focus on the professional and personal well-being of our employees, as well as a flexible approach to work tasks, Takeda Kazakhstan has been awarded the prestigious Top Employer certification by the renowned independent international organization Top Employers Institute for several consecutive years.

The four main therapeutic areas of our company are: hematology, oncology, rare diseases, and gastroenterology. In Kazakhstan, the company specializes in treating socially significant diseases such as mucopolysaccharidosis type II (Hunter syndrome), Fabry disease, Hodgkin lymphoma, multiple myeloma, inflammatory bowel disease, hereditary angioedema, and hemophilia. Today, Takeda's portfolio in Kazakhstan includes around 30 drugs, 10 of which are vital innovative medicines.

Takeda Kazakhstan strives to be a partner to the state and the healthcare system. This involves organizing educational seminars and training for medical professionals, maintaining ongoing dialogue with the medical community, and promptly informing it about global medical innovations that can enhance patients' quality of life and allow even those with severe illnesses to live fully.